Larimar Therapeutics, Inc.

NasdaqGM LRMR

Larimar Therapeutics, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Larimar Therapeutics, Inc. EBT Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGM: LRMR

Larimar Therapeutics, Inc.

CEO	Dr. Carole S. Ben-Maimon M.D.
IPO Date	June 19, 2014
Location	United States
Headquarters	Three Bala Plaza East
Employees	42
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Key trends

Past 5 years